Has Tilak Mallik, MD received payments from drug or device companies?

Yes. Drug and device makers reported $77,503 in general payments to Tilak Mallik, MD across 995 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tilak Mallik, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tilak Mallik, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tilak Mallik, MD

Endocrinology, Diabetes & Metabolism · Marrero, LANPI 1437160959

Payments from drug & device makers

$77,503in general payments, 2019–2025

Across 995 payments — averaging $77.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$24K
Amgen$22K
Merck$8K
Novo Nordisk$4K
Corcept Therapeutics$4K
Shire North American Group Inc$2K
plus $13K from 49 others

$39,145in research payments, 2019–2025

Across 34 payments — averaging $1151.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$39K
Sanofi US Services Inc.$350

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	22	$23,980
Amgen(2 entities)	98	$22,262
Merck	45	$7,559
Novo Nordisk	150	$4,452
Corcept Therapeutics	11	$3,780
Shire North American Group Inc	5	$2,252
Boehringer Ingelheim	66	$1,395
AbbVie	63	$1,140
Lilly USA, LLC	61	$1,111
Xeris Pharmaceuticals, Inc.	55	$1,033
Sanofi-aventis U.S. LLC	49	$962
AstraZeneca(2 entities)	47	$918
Abbott	38	$817
Bayer	37	$678
Medtronic(2 entities)	25	$572
Esperion Therapeutics, Inc.	18	$491
Dexcom, Inc.	25	$437
Amneal Pharmaceuticals LLC	31	$424
Valeritas, Inc.	13	$299
IBSA Pharma Inc.	13	$261
Averitas Pharma Inc.	4	$208
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	10	$189
Ascendis Pharma Endocrinology Inc	5	$171
Amarin Pharma, Inc.	7	$155
Radius Health, Inc.	9	$145
Vistapharm, Inc.	7	$138
Novartis	6	$129
Pfizer	5	$107
BETA Bionics, Inc.	5	$106
Regeneron	1	$106
BD	5	$99
Regeneron Healthcare Solutions, Inc.	5	$99
Mannkind Corporation	5	$87
Nevro Corp.	4	$87
Insulet Corporation	4	$68
Recordati_rare_diseases_inc.	3	$65
Zealand Pharma US, Inc.	4	$64
Amryt Pharma Holdings Ltd	3	$62
Ascensia Diabetes Care US Inc.	3	$62
GRT US Holding, Inc.	3	$62
Ultragenyx Pharmaceutical Inc.	3	$51
Neurocrine Biosciences, Inc.	2	$49
GSK	2	$47
Almatica Pharma LLC	2	$46
Johnson & Johnson	3	$43
Kowa Pharmaceuticals America, Inc.	3	$42
Sequel Med Tech, LLC	1	$35
Eisai Inc.	2	$32
Antares Pharma, Inc.	1	$25
Rhythm Pharmaceuticals, Inc.	1	$22
EUSA Pharma (US) LLC	1	$20
Alfasigma USA, Inc.	1	$16
Currax Pharmaceuticals LLC	1	$15
Lifescan, Inc.	1	$15
Cequr Corporation	1	$14

How this compares

$77,503 in reported general payments places this provider in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana →

Medicare billing

Part B allowed, 2024

$91,231

Medicare patients

228

Services billed

647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Marrero

Marideli ScanlanMarrero$446K
Alejandra Riera GonzalezMarrero$7K
Sarah KeslerMarrero$5K
Amy VarugheseMarrero$3K
Tuan Huy TranMetairie$2M
Harold MillerHammond$1.1M
Timothy GilbertBaton Rouge$985K
Justin FontenotLafayette$905K
Vivian FonsecaNew Orleans$700K
Frank GreenwayBaton Rouge$669K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →